Indicators of the osteoclastogenesis system in men with different clinical types of ankylosing spondylitis
https://doi.org/10.14412/1996-7012-2015-2-23-27
Abstract
Objective: to evaluate the osteoclastogenesis regulatory system – osteoprotegerin/receptor activator of nuclear factor-κβ ligand (OPG/RANKL) system – in men with different clinical types of ankylosing spondylitis (AS).
Subjects and methods. The osteoclastogenesis regulatory system was studied in 60 men, including 40 patients diagnosed with AS complying with the 1984 New York criteria and 20 men without AS. RANKL, a major stimulant of osteoclastogenesis, and OPG, a decoy receptor that binds RANKL and, accordingly, blocks osteoclastogenesis, were investigated.
Results. It was shown that in the patients with AS, RANKL concentrations were normal and the content of OPG and OPG/RANKL ratio proved to be significantly higher than those in the men without AS. The highest OPG concentrations were recorded in patients with the axial form of this disease, its moderate activity and early X-ray stage. No relationship was found between the level of RANKL and the clinical characteristics of AS; however, there was a tendency to a slight increase in its concentration in patients with extraskeletal manifestations of AS, its high activity, high functional class, and late X-ray stage.
Conclusion. The considerable increase in OPG levels and OPG/RANKL ratio was ascertained to be associated to the fact that 94% of the patients with late-stage AS characterized by the presence of numerous syndesmophytes. These changes must be compensatory in response to modestly increased RANKL level and enhanced bone resorption.
About the Authors
T. A. Raskina
Kemerovo State Medical Academy, Ministry of Health of Russia, Kemerovo, Russia 22A, Voroshilov St., Kemerovo 650036
Russian Federation
Russian Federation
O. A. Pirogova
Kemerovo State Medical Academy, Ministry of Health of Russia, Kemerovo, Russia 22A, Voroshilov St., Kemerovo 650036
Russian Federation
Russian Federation
O. V. Zobnina
Regional Clinical Hospital for War Veterans, Kemerovo, Russia 10, 50 Let Oktyabrya St., Kemerovo 650000
Russian Federation
Russian Federation
G. A. Pintova
Research Institute for Complex Problems of Hygiene and Occupational Diseases, Novokuznetsk, Russia 23, Kutuzov St., Novokuznetsk 654000
Russian Federation
Russian Federation
References
1. Мясоутова ЛИ, Лапшина СА, Салихов ИГ, Васильев АГ. Изменение минеральной плотности костной ткани у больных анкилозирующим спондилоартритом. Остеопороз и остеопатии. 2011;(3):14–8. [Myasoutova LI, Lapshina SA, Salikhov IG, Vasil'ev AG. The change in mineral bone density in patients with ankylosing spondylitis. Osteoporoz i osteopatii. 2011;(3):14–8. (In Russ.)].
2. Насонов ЕЛ. Вторичный остеопороз: патогенез и клиническое значение при воспалительных заболеваниях суставов. Остеопороз и остеопатии. 1998;(1):18–20. [Nasonov EL. Secondary osteoporosis: pathogenesis and clinical significance in inflammatory diseases of the joints. Osteoporoz i osteopatii. 1998;(1):18–20. (In Russ.)].
3. Скрипникова ИА, Косматова ОИ, Оганов РГ. Инновационные методы лечения остеопороза: ингибиторы RANKL. Профилактическая медицина. 2011;(2):23–30. [Skripnikova IA, Kosmatova OI, Oganov RG. Innovative methods of treatment of steoporosis: the RANKL inhibitors. Profilakticheskaya meditsina. 2011;(2):23–30. (In Russ.)].
4. Юшина СА. Особенности метаболизма костной ткани у больных анкилозирующим спондилоартритом. Автореферат на соискание ученой степени кандидата медицинских наук. Оренбург; 2012. [Yushina SA. Osobennosti metabolizma kostnoi tkani u bol'nykh ankiloziruyushchim spondiloartritom. Avtoreferat na soiskanie uchenoi stepeni kandidata meditsinskikh nauk [Features of bone metabolism in patients with ankylosing spondylitis. Author's abstract on competition of a scientific degree of cand. med. sci.]. Orenburg; 2012. (In Russ.)].
5. Haynes DR, Crotti TN, Loric M, et al. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts formation by cells in the human rheumatoid arthritis joint. Rheumatology (Oxford). 2001 Jun;40(6):623–30.
6. Ермакова ИП. Биохимические маркеры обмена костной ткани и их клиническое использование. Лаборатория. 2001;(1):3–5. [Ermakova IP. Biochemical markers of bone metabolism and their clinical use. Laboratoriya. 2001;(1):3–5. (In Russ.)].
7. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999 May 3;145(3):527–38.
8. Bronson WD, Walker SE, Hillman LS, et al. Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis. J Rheumatol. 1998 May;25(5):929–35.
9. Ruof J, Stucki G. Comparison of the Dougados Functional Index and the Bath Ankylosing Spondylitis Functional Index: a literature review. J Rheumatol. 1999 Apr;26(4):955–60.
10. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999 May 3;145(3):527–38.
11. Kim HR, Lee SH, Kim HY. Elevated serum levels of soluble receptor activator of nuclear factors-kB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis. Rheumatology (Oxford). 2006 Oct;45(10):1197–200. Epub 2006 Mar 27.
12. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclasts differentiation and activation. Cell. 1998 Apr 17;93(2):165–76.
13. Anandaraiah AP. Role of RANKL in bone diseases. Trends Endocrinol Metab. 2009 Mar;20(2):88–94. doi: 10.1016/j.tem.2008.10.007. Epub 2009 Jan 29.
14. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclasts differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA. 1999 Mar 30;96(7):3540–5.
15. Kartsogiannis V, Zhou H, Horwood NJ, et al. Localization of RANKL mRNA and protein in skeletal and extraskeletal tissues. Bone. 1999 Nov;25(5):525–34.
16. Schett G, Hayer S, Zwerina J, et al. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol. 2005 Nov;1(1):47–54.
17. Картамышева НН, Чумакова ОВ. Костное ремоделирование как модель межклеточных взаимодействий (обзор литературы). Нефрология и диализ. 2004;6(1):43–6. [Kartamysheva NN, Chumakova OV. Bone remodeling as a model of intercellular interactions (literature review). Nefrologiya i dializ. 2004;6(1):43–6. (In Russ.)].
18. Analay Y, Ozcan E, Karan A, et al. The effectiveness of intensive group exercise on patients with ankylosing spondylitis. Clin Rehabil. 2003 Sep;17(6):631–6.
19. Neumann E, Gay S, Mü ller-Ladner U. The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum. 2005 Oct;52(10):2960–7.
20. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factors-kB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008 Apr;29(2):155–92. Epub 2007 Dec 5.
21. Chen CH, Chen HA, Liao HT, et al. Soluble receptor activator of nuclear factor – κB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol. 2010 Oct;29(10):1155–61. doi: 10.1007/s10067-010-1543-y. Epub 2010 Aug 6.
22. Haynes DR, Barg E, Crotti TN, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies, osteoarthritis and normal patients. Rheumatology (Oxford). 2003 Jan;42(1):123–34.
23. Simonet WS1, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997 Apr 18;89(2):309–19.
24. Grisar J, Bernecker PM, Aringer M, et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol. 2002 Jul;29(7):1430–6.
25. Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients ith ankylosing spondylitis. J Rheumatol. 2004 Nov;31(11):2236–41.
Review
For citations:
Raskina TA, Pirogova OA, Zobnina OV, Pintova GA. Indicators of the osteoclastogenesis system in men with different clinical types of ankylosing spondylitis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2015;9(2):23-27. (In Russ.) https://doi.org/10.14412/1996-7012-2015-2-23-27
Views:
1521
Email this article 